Home › Trial NCT02403778
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
- Trial IDNCT02403778
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorUniversity of Colorado, Denver
- Enrollment10
- Start date2015-12-17
- ConditionsMelanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.